How Resistance Training Becomes Metabolic Medicine

Keywords: Resistance Training, Metabolic Health, AMPK, mTOR, Myokines, GLUT4, Insulin Resistance, Type 2 Diabetes, Visceral Adiposity, Lipid Metabolism, Mitochondrial Biogenesis, Longevity

Introduction

The global burden of metabolic disease has reached epidemic proportions. As of 2024, an estimated 537 million adults worldwide live with type 2 diabetes mellitus (T2DM), with projections exceeding 780 million by 2045. Metabolic syndrome, a clinical constellation of central obesity, dyslipidaemia, insulin resistance, and hypertension affects approximately one quarter of the world’s adult population. These conditions are not merely chronic inconveniences; they represent the upstream drivers of cardiovascular disease, chronic kidney disease, non-alcoholic fatty liver disease, and certain cancers, collectively responsible for the majority of preventable premature mortality in high-income nations and an ever-growing share in low- and middle-income countries [27].

Against this backdrop, the pharmaceutical industry has delivered remarkable tools like metformin, GLP-1 receptor agonists, SGLT-2 inhibitors that meaningfully alter disease trajectories. Yet a powerful, universally available, low-cost intervention has long been under prescribed and underappreciated: structured resistance training. While public health messaging has historically centred on aerobic exercise as the cornerstone of metabolic health, a growing and compelling body of evidence positions RT as an equally and in many respects uniquely valuable metabolic therapeutic. Lifting weights, pulling cables, pressing resistance: these are not merely bodybuilding pursuits. They are molecular medicine [27].

The distinction matters because skeletal muscle, the primary target of RT, is not merely a contractile tissue. It is the body’s largest metabolic sink. Skeletal muscle accounts for approximately 80% of insulin-stimulated glucose uptake and is the principal site of de novo fatty acid oxidation during exercise. RT-induced adaptations in muscle, from the molecular signaling cascades initiated within seconds of a first contraction, to the architectural remodeling of muscle fibres over weeks of training have profound downstream consequences for the entire metabolic ecosystem of the human body [5,8].

This article is written for a science-literate audience that includes clinicians, researchers, health technology professionals, and informed health advocates. Our goal is to deconstruct the mechanistic pathways through which resistance training exerts its metabolic effects, survey the clinical evidence for each domain, and translate these insights into practical frameworks for metabolic disease prevention, particularly in the context of longevity-focused health strategies.

Skeletal Muscle: More Than Movement

Architecture and Metabolic Significance

Human skeletal muscle is a morphologically complex and metabolically heterogeneous tissue. At the gross anatomical level, the adult human body contains more than 600 individual skeletal muscles, comprising between 30 and 40 percent of total body mass in typical adults and upward of 50 percent in highly trained individuals. This mass is not metabolically inert. At rest, skeletal muscle accounts for approximately 20–30% of basal metabolic rate; during vigorous physical activity, this contribution can rise to over 90% of total energy expenditure [8].

At the cellular level, skeletal muscle is composed of individual myofibers, multinucleated cells that are among the largest in the human body, sometimes exceeding 30 centimeters in length. These fibers are classified into two broad phenotypic categories: Type I (slow-twitch, oxidative) fibers, which are fatigue-resistant and rely predominantly on aerobic metabolism, and Type II (fast-twitch, glycolytic) fibers, which generate greater force rapidly but fatigue more quickly. In the context of metabolic disease, Type II fibers are of particular interest: they constitute the largest proportion of muscle mass in humans, and they are disproportionately impaired in insulin-resistant states [5].

Importantly, skeletal muscle is the quantitatively dominant site of insulin-stimulated glucose disposal. Under euglycaemic hyperinsulinaemic clamp conditions, the gold standard for measuring insulin sensitivity, skeletal muscle accounts for more than 80% of glucose uptake stimulated by physiological insulin concentrations. It is therefore not surprising that reduced skeletal muscle mass (sarcopenia) and quality (myosteatosis, intramuscular fat infiltration) are strongly associated with insulin resistance and T2DM risk, independent of total body adiposity [5].

The Endocrine muscle: A Paradigm Shift

The conceptual revolution in skeletal muscle biology came with the recognition, advanced largely through the work of Pedersen and colleagues, that contracting skeletal muscle functions as an endocrine organ, releasing a diverse array of peptide and protein factors termed “myokines” into the circulation. The term was first coined by Pedersen in 2003 to describe interleukin-6 (IL-6) released during muscle contraction, but the myokine secretome has since expanded to encompass more than 600 candidate molecules, including irisin, brain-derived neurotrophic factor (BDNF), fibroblast growth factor 21 (FGF21), myostatin, follistatin, and meteorin-like protein (Metrnl), among others [1,2].

These factors serve as molecular messengers that communicate the exercise state of skeletal muscle to distant organs and tissues, including adipose tissue, liver, pancreas, gut, brain, and bone. Through this endocrine function, RT does not merely affect the muscle itself, it reconfigures the metabolic communication network of the entire body. This insight fundamentally reframes the biological rationale for resistance exercise prescription in metabolic disease management [1,2,27].

Molecular Mechanisms: The Signaling Cascade of Resistance Exercise

The Energy Sensor: AMPK

The moment a muscle fibre begins to contract under load, its energy demands escalate dramatically. ATP is hydrolysed to ADP, and the cellular AMP:ATP ratio rises sharply. This metabolic perturbation is detected by AMP-activated protein kinase (AMPK), a heterotrimer consisting of a catalytic alpha subunit and regulatory beta and gamma subunits. The gamma subunit contains adenine nucleotide-binding domains; when AMP binds, indicating energetic stress, it triggers conformational changes that dramatically increase AMPK activity, partly by making the enzyme a better substrate for its upstream kinase, liver kinase B1 (LKB1) [6].

Once activated, AMPK functions as a master metabolic regulator, switching cells from anabolic to catabolic programs. Its principal actions in the context of RT and metabolic health include: (1) phosphorylation and activation of glucose transporter type 4 (GLUT4) translocation, enabling insulin-independent glucose uptake; (2) phosphorylation of acetyl-CoA carboxylase (ACC), reducing malonyl-CoA production and disinhibiting carnitine palmitoyltransferase-1 (CPT-1), thereby increasing fatty acid oxidation; (3) phosphorylation and activation of PGC-1α, driving mitochondrial biogenesis and (4) inhibition of mTOR complex 1 (mTORC1), transiently suppressing energy-costly anabolic processes during exercise [5,6,7,11].

Crucially, AMPK activation by exercise has been shown to persist for hours post-exercise, contributing to the prolonged improvements in insulin sensitivity observed following a single bout of resistance training. In insulin-resistant and diabetic muscle, where the canonical insulin signaling cascade is impaired, AMPK-dependent glucose uptake provides an alternative insulin-independent pathway, one that is preserved even in the setting of substantial insulin resistance. This gives RT a mechanistic advantage that few pharmaceutical agents can match: it bypasses the principal molecular defect of T2DM at its site of greatest metabolic consequence [5,8,12].

The Anabolic Signal: mTOR and Muscle Protein Synthesis

While AMPK dominates the acute metabolic response to exercise-induced energetic stress, the mechanistic target of rapamycin (mTOR) and specifically its complex 1 form (mTORC1), orchestrates the longer-term anabolic adaptation. mTORC1 is activated by mechanical stimuli (transduced through the integrin-linked kinase and Akt pathways), by branched-chain amino acids (particularly leucine, acting through Ragulator-Rag GTPase complexes), and by growth factors including insulin-like growth factor 1 (IGF-1). In the hours following a bout of RT, rising systemic amino acid availability and growth factor signalling tip the balance in favour of mTORC1 activation [7].

Activated mTORC1 phosphorylates two primary downstream effectors: S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). The net result is a marked upregulation of protein synthesis, the molecular basis of muscle hypertrophy. This is metabolically relevant because greater muscle mass directly expands the body’s glucose disposal capacity, fatty acid oxidation capacity, and resting energy expenditure. Each kilogram of additional lean mass increases resting metabolic rate by an estimated 13 kcal/day, a seemingly modest number that accumulates meaningfully over years and decades of maintained muscle mass [7,8].

The temporal interplay between AMPK and mTOR during and after RT is elegantly choreographed: AMPK dominates during the exercise bout (suppressing mTOR to prioritize energy conservation), while mTOR ascends in the recovery phase as energetic homeostasis is restored and anabolic substrates become available. Understanding this dynamic has informed practical recommendations regarding post-exercise protein intake, specifically, the rationale for consuming 20–40 g of high-quality protein within 2–3 hours post-RT to maximally stimulate mTOR-dependent muscle protein synthesis [6,7,28].

PGC-1α: The Bridge Between Contraction and Mitochondrial Adaptation

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator that coordinates the nuclear and mitochondrial gene expression programs responsible for mitochondrial biogenesis and oxidative metabolism. It is activated downstream of both AMPK (via direct phosphorylation) and calcium-calmodulin-dependent protein kinase II (CaMKII, which responds to calcium transients during muscle contraction), making it a convergence point for multiple exercise-sensing pathways [8,11].

Once activated, PGC-1α binds to and coactivates several transcription factors, including nuclear respiratory factor 1 (NRF-1) and NRF-2, which in turn upregulate mitochondrial transcription factor A (TFAM), the master regulator of mitochondrial DNA transcription and replication. The net outcome is an increase in mitochondrial content, improved mitochondrial morphology (favouring fused, elongated networks with greater electron transport chain efficiency), and enhanced oxidative capacity. In insulin-resistant muscle, which is characterised by mitochondrial dysfunction, reduced oxidative phosphorylation capacity, and increased intramyocellular lipid accumulation, RT-induced PGC-1α activation represents a direct molecular rescue [11,21].

Notably, PGC-1α also regulates expression of GLUT4 (through interaction with myocyte enhancer factor 2, MEF2) and drives the expression of several myokines including irisin (through FNDC5 transcription), linking mitochondrial adaptation to systemic metabolic benefits. PGC-1α thus serves as the molecular bridge between the acute mechanical stimulus of resistance exercise and the systemic, long-term metabolic adaptations that define its therapeutic value [9,11].

The Myokine Revolution: Muscle as a Systemic Metabolic Regulator

Interleukin-6: The Prototypical Exercise Myokine

IL-6 was the first myokine to be identified and remains the most extensively studied. During exercise, circulating IL-6 concentrations can rise 10- to 100-fold above resting levels, with the magnitude of increase correlating with exercise intensity, duration, and the muscle mass recruited. Crucially, muscle-derived IL-6 released during exercise differs functionally from IL-6 produced by macrophages in the setting of chronic inflammation, the former occurs in the absence of tumor necrosis factor-alpha (TNF-α) and is predominantly anti-inflammatory in its downstream effects [1,2].

In terms of metabolic actions, exercise-induced IL-6 stimulates AMPK activity in skeletal muscle, liver, and adipose tissue, promoting glucose uptake and fatty acid oxidation. It acts on the liver to stimulate hepatic glucose production (important for maintaining glycaemia during prolonged exercise) and on adipose tissue to enhance lipolysis. IL-6 also directly stimulates the secretion of GLP-1 from intestinal L cells and glucagon-like peptide from the gut, offering a mechanistic link between muscle contraction and pancreatic beta-cell function [2,6,10].

In the context of metabolic disease, the anti-inflammatory IL-6 response to RT is of particular therapeutic relevance. Chronic low-grade inflammation, characterized by elevated resting concentrations of TNF-α, IL-1β, and C-reactive protein (CRP) is a hallmark of insulin resistance, T2DM, and metabolic syndrome, and contributes directly to impaired insulin signaling. The repeated, transient anti-inflammatory IL-6 surges induced by regular RT training have been proposed to blunt this chronic inflammatory milieu, in part through upregulation of anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist) and suppression of TNF-α and IL-1β production [2,4,5].

Irisin: The Exercise Hormone

Irisin, encoded by the FNDC5 gene and cleaved from its transmembrane precursor during exercise, attracted extraordinary attention following its identification by Boström and colleagues in 2012. Originally characterized as a myokine that drives “browning” of white adipose tissue, stimulating the expression of uncoupling protein 1 (UCP1) in white adipocytes, thereby increasing thermogenic energy expenditure, irisin has subsequently been shown to exert direct metabolic effects in multiple tissues [9,10].

In skeletal muscle, irisin activates the p38 mitogen-activated protein kinase (p38/MAPK), PGC-1α axis, sustaining glucose uptake and mitochondrial activity. In human myotubes, irisin promotes glucose and lipid metabolism through AMPK phosphorylation in an exercise-dependent manner. In the liver, irisin suppresses hepatic gluconeogenesis and reduces ectopic lipid accumulation. In bone, irisin is anabolic, with compelling murine data and emerging human evidence suggesting that RT-induced irisin increases bone mineral density [9,10].

Resistance training consistently elevates circulating irisin concentrations in both acute and chronic training paradigms, with the magnitude of response varying by exercise intensity and volume. Importantly, circulating irisin concentrations are reduced in individuals with obesity, T2DM, and metabolic syndrome compared to healthy controls, suggesting that the irisin-mediated communication pathway between muscle and peripheral tissues is impaired in metabolic disease, and that RT-induced restoration of irisin signaling may be mechanistically important for its metabolic benefits in these populations [9,10].

Additional Myokines of Metabolic Relevance

Beyond IL-6 and irisin, several additional exercise-induced myokines merit consideration. Fibroblast growth factor 21 (FGF21), primarily known as a hepatokine, is also produced by skeletal muscle in response to exercise and promotes fatty acid oxidation in adipocytes while improving hepatic insulin sensitivity. Meteorin-like protein (Metrnl) is induced by exercise and promotes adipose tissue browning and anti-inflammatory macrophage polarisation. Follistatin, upregulated by RT, antagonises myostatin, the endogenous inhibitor of muscle growth and thereby amplifies hypertrophic responses and improves the lean-to-fat mass ratio [2,10,22].

Myostatin itself is of particular metabolic significance. As a member of the TGF-beta superfamily, myostatin limits skeletal muscle mass and promotes adipogenesis. RT consistently reduces circulating myostatin concentrations and downregulates myostatin expression in skeletal muscle, thereby removing a braking constraint on both muscle growth and fat-mass reduction. Individuals with high myostatin expression, including sedentary older adults and those with sarcopenic obesity may derive particularly pronounced metabolic benefits from RT, as the myostatin-suppressive effect of training removes a major impediment to metabolic recovery [22].

Collectively, the myokine secretome generated by resistance exercise constitutes a sophisticated molecular language through which working muscle instructs distant tissues to shift toward a metabolically favorable phenotype: increased fatty acid oxidation in adipose tissue, suppressed hepatic gluconeogenesis, enhanced pancreatic insulin secretion, reduced systemic inflammation, and improved insulin sensitivity across multiple organs. This endocrine dialogue between contracting muscle and its target organs is perhaps the most compelling argument for conceptualizing RT as systemic metabolic medicine rather than merely a strategy for muscle building [1,2,27].

Key Insight is that muscle as an endocrine organ. Regular resistance training generates repeated pulses of myokines, including IL-6, irisin, FGF21, and follistatin that collectively reprogram the metabolic behavior of adipose tissue, liver, pancreas and brain. This endocrine function of contracting muscle is activated even in the setting of profound insulin resistance, making RT therapeutically effective across the full spectrum of metabolic disease severity [1,2,5,10,27].

Insulin Resistance and Glycaemic Control: From GLUT4 to HbA1c

The Pathophysiology of Insulin Resistance in Skeletal Muscle

Insulin resistance, the diminished capacity of insulin to stimulate glucose uptake in its primary target tissues, is the central molecular defect linking obesity, T2DM, and metabolic syndrome. In skeletal muscle, the canonical mechanism involves impaired signaling downstream of the insulin receptor. Normally, insulin binding to its receptor activates receptor tyrosine kinase activity, leading to phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), activation of phosphoinositide 3-kinase (PI3K), generation of phosphatidylinositol-3,4,5-trisphosphate (PIP3), and sequential activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and Akt (protein kinase B). Activated Akt then phosphorylates the Akt substrate of 160 kDa (AS160/TBC1D4), relieving its inhibitory effect on Rab GTPases and enabling the translocation of GLUT4-containing vesicles to the plasma membrane and T-tubules, the rate-limiting step for insulin-stimulated glucose uptake [5,12].

In insulin-resistant muscle, this cascade is impaired at multiple points, most commonly through serine phosphorylation of IRS-1 by inflammatory kinases (including JNK and IKKβ, activated by intramyocellular lipid metabolites such as diacylglycerol and ceramides) and through reduced GLUT4 expression. The result is an impaired ability to translocate GLUT4 vesicles in response to insulin, leaving postprandial blood glucose elevated and placing an increased burden on pancreatic beta cells to compensate by secreting ever-larger amounts of insulin [5].

How Resistance Training Restores GLUT4- Mediated Glucose Uptake

Resistance exercise activates GLUT4 translocation through an alternative, insulin-independent pathway, primarily mediated by AMPK and calcium-calmodulin-dependent pathways, that bypasses the molecular defects of insulin resistance. Muscle contraction elevates intracellular calcium (which activates CaMKII and CaMKK, an alternative upstream kinase of AMPK) and increases the AMP:ATP ratio (activating AMPK via LKB1), both of which independently drive GLUT4 vesicle translocation through AS160 phosphorylation [5,6,12].

Crucially, RT does more than acutely enhance GLUT4 translocation. Chronic training increases GLUT4 protein expression in skeletal muscle, an adaptation that manifests within days to weeks of initiating a resistance training programme and is maintained as long as training continues. A landmark early study demonstrated that trained muscles contain up to twice the GLUT4 protein content of untrained muscles. More recent transcriptomic analyses have shown that RT upregulates GLUT4 gene expression (SLC2A4) through multiple transcription factors, including MEF2, HDAC5 (whose exercise-induced nuclear export relieves its suppression of GLUT4 transcription), and PGC-1α [5,11,12].

The functional consequence of increased GLUT4 expression is an enhanced maximal capacity for glucose uptake, a kind of widening of the metabolic road through which blood glucose can flow into muscle cells. This adaptation helps to explain why RT improves glycaemic control in both the short term (through acute AMPK-mediated translocation) and the long term (through chronic upregulation of GLUT4 expression and muscle mass expansion, effectively enlarging the total glucose disposal capacity of the body) [3,5,12].

Clinical Evidence for Glycaemic Improvement

The clinical literature robustly supports the glycaemic benefits of RT. A 2023 meta-analysis published in Frontiers in Endocrinology, including 26 randomized controlled trials with 1,336 participants, found that resistance training significantly reduced HbA1c (mean difference: −0.51%, 95% CI: −0.74 to −0.29%) and fasting blood glucose compared to non-exercise control conditions in individuals with T2DM. High-intensity resistance training was more effective than low-to-moderate intensity training for HbA1c reduction, suggesting a dose-response relationship consistent with the mechanistic importance of the magnitude of metabolic perturbation induced by each exercise bout [13].

A systematic review and meta-analysis in Diabetes Research and Clinical Practice (2025) confirmed these findings specifically in older adults with T2DM, a population at heightened metabolic risk due to concurrent sarcopenia and age-related declines in insulin sensitivity. The authors found that resistance exercise training significantly improved HbA1c, fasting glucose, and measures of physical function compared to control conditions [14].

A comprehensive network meta-analysis encompassing 158 studies and 17,059 participants, published in 2025, compared aerobic exercise, resistance exercise, combined exercise, and physical activity advice for HbA1c improvement in individuals with T2DM.Combined exercise (aerobic plus resistance) consistently ranked highest for glycaemic benefit, but resistance training alone was robustly superior to control and equivalent to physical activity advice interventions. These findings reinforce RT as a standalone therapeutic modality for glycaemic management, not merely an adjunct to aerobic conditioning [15,16].

Body Composition, Visceral Adiposity, and Resting Metabolism

The Metabolic Toxicity of Visceral Fat

Not all adiposity is metabolically equivalent. While subcutaneous adipose tissue, the fat deposited beneath the skin is relatively metabolically inert, visceral adipose tissue (VAT) fat accumulated within the abdominal cavity around the liver, intestines, and mesentery is highly active and profoundly deleterious. VAT adipocytes are larger, more lipolytically active, and more inflammatory than their subcutaneous counterparts. They secrete elevated quantities of pro-inflammatory adipokines (including TNF-α, IL-6 from an inflammatory context, and resistin) and reduced quantities of the insulin-sensitising adipokine adiponectin. Lipolysis from VAT delivers free fatty acids directly into the portal circulation, where they reach the liver in high concentrations, contributing to hepatic insulin resistance, increased VLDL production, and non-alcoholic fatty liver disease [17].

VAT is therefore not merely a biomarker of metabolic risk, it is an active driver of the inflammatory and insulin-resistant milieu that characterises metabolic syndrome and T2DM. Computed tomography and MRI studies have consistently demonstrated that VAT, independent of total body weight or BMI, is among the strongest predictors of insulin resistance, T2DM incidence, cardiovascular disease risk, and all-cause mortality [17].

Resistance Training and Visceral Fat Reduction

A 2024 systematic review and network meta-analysis in Obesity Reviews, encompassing 84 randomized controlled trials examining different exercise modalities on visceral adipose tissue, found that all exercise types reduced VAT compared to control. Resistance training was effective at reducing VAT, with combined aerobic and resistance training demonstrating the greatest overall reductions. This is mechanistically plausible given the distinct and complementary pathways by which each modality mobilizes fat: aerobic exercise primarily drives acute lipid oxidation and creates caloric deficit, while RT reduces VAT through long-term elevation of resting metabolic rate and improvements in insulin sensitivity that reduce ongoing fat deposition [17].

An important and often underappreciated advantage of RT over aerobic exercise in the context of weight management is its superior ability to preserve lean mass during caloric restriction. A systematic review and meta-analysis in 2025 (Frontiers in Endocrinology) found that resistance training as a primary weight-loss strategy preserved lean body mass more effectively than aerobic exercise while achieving comparable fat mass reduction. This is metabolically crucial because lean mass preservation prevents the decline in resting metabolic rate (RMR) that invariably accompanies weight loss through caloric restriction alone, the physiological substrate for the well-documented weight regain phenomenon following diet-only interventions [18].

Lean Mass and Resting Metabolic Rate; The Long-Term Metabolic Dividend

Skeletal muscle is the largest metabolically active tissue in the human body, and its mass is the dominant determinant of RMR, the energy expended at rest that constitutes 60–75% of total daily energy expenditure in sedentary individuals. The metabolic value of lean mass is therefore not trivial. Each additional kilogram of skeletal muscle is estimated to increase RMR by approximately 13–17 kcal/day through increased basal protein turnover, ion pumping (particularly sodium-potassium ATPase activity), and maintenance of mitochondrial density [8].

Importantly, the RMR elevation following RT extends well beyond the training session itself. The excess post-exercise oxygen consumption (EPOC), sometimes termed the “afterburn effect” is particularly pronounced after high-intensity resistance exercise, with some studies documenting elevated oxygen consumption for up to 38 hours post-RT. This prolonged EPOC reflects the energy cost of restoring phosphocreatine stores, repairing exercise-induced muscle damage, synthesizing new muscle protein, and restoring hormonal and ionic homeostasis [30].

The implication for longevity-focused health strategy is powerful: investing in skeletal muscle mass through RT during midlife and beyond creates a metabolic infrastructure, a larger, more metabolically active, more insulin-sensitive lean mass that provides compounding metabolic dividends across decades. Conversely, the progressive sarcopenia of sedentary aging (loss of 3–8% of muscle mass per decade after age 30, accelerating after age 60) creates a progressively more hostile metabolic environment, with declining RMR, worsening insulin sensitivity, and increasing adiposity even in the absence of changes in caloric intake [14,18,24].

Lipid Metabolism and Cardiovascular Risk Reduction

The Lipid Abnormalities of Metabolic Syndrome

Atherogenic dyslipidaemia, elevated fasting and postprandial triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), and the predominance of small, dense low-density lipoprotein (LDL) particles is a defining feature of metabolic syndrome and a major driver of cardiovascular disease risk in this population. This pattern arises largely from hepatic overproduction of VLDL (driven by insulin resistance and increased portal free fatty acid flux from VAT), impaired lipoprotein lipase (LPL) activity (reducing VLDL triglyceride clearance), and reduced HDL synthesis [19,20].

Standard lipid panels that report only total cholesterol, LDL-C, HDL-C, and triglycerides may underestimate cardiovascular risk in metabolically unhealthy individuals. The atherogenic index of plasma (AIP = log[triglycerides/HDL-C]) and LDL particle number are superior predictors of residual cardiovascular risk in insulin-resistant populations, and both are substantially improved by the metabolic improvements induced by RT [19].

Resistance Training Effects on the Lipid Profile

A comprehensive systematic review and meta-analysis published in Sports Medicine (2024/2025), incorporating 148 randomized controlled trials with 8,673 participants, examined the effects of exercise training on blood lipids. The analysis found significant improvements across all lipid parameters with exercise training: total cholesterol decreased by 5.90 mg/dL, LDL-C decreased by 7.22 mg/dL, HDL-C increased by 2.11 mg/dL, triglycerides decreased by 8.01 mg/dL, and VLDL decreased by 3.85 mg/dL.¹⁹ While aerobic training demonstrated somewhat stronger effects on LDL-C reduction, RT contributed meaningfully to improvements in triglycerides and HDL-C, the components of the lipid profile most pathologically affected in metabolic syndrome [19,20].

The mechanisms by which RT improves lipid metabolism are multifactorial. First, by increasing skeletal muscle LPL activity, the enzyme responsible for hydrolyzing triglyceride-rich lipoproteins (VLDL and chylomicrons) at the capillary endothelium, RT enhances postprandial triglyceride clearance. Second, by reducing VAT and improving insulin sensitivity, RT decreases hepatic VLDL overproduction, addressing the lipid problem at its source. Third, by stimulating skeletal muscle fatty acid oxidation (via AMPK activation of CPT-1 and upregulation of oxidative enzymes), RT increases the disposal of circulating free fatty acids, reducing the substrate available for re-esterification into VLDL triglycerides [6,8,17].

A meta-analysis specifically examining strength training combined with dietary modification in overweight and obese subjects found that endurance-strength combined training more effectively decreased total cholesterol, LDL-C, and triglycerides than strength training alone, supporting the complementary nature of the two modalities. However, even as a standalone intervention, resistance training consistently produced clinically meaningful improvements in the lipid parameters most strongly associated with cardiovascular risk in the metabolically unhealthy [19,20].

Beyond the Lipid Panel: Postprandial Metabolism

Emerging evidence highlights the importance of postprandial, rather than fasting, lipid metabolism for cardiovascular risk. Postprandial lipaemia, the prolonged elevation of triglyceride-rich lipoproteins following a fat-containing meal is an independent cardiovascular risk factor, and one that is poorly captured by conventional fasting lipid panels. Skeletal muscle LPL activity is a primary determinant of the rate of clearance of chylomicrons and VLDL from the circulation after meals. By upregulating LPL activity in the large skeletal muscle mass, RT may exert its most clinically relevant lipid-lowering effects in the postprandial state, effects that are invisible on standard fasting laboratory panels but profoundly important for the ongoing burden of atherosclerotic vascular disease [8,19].

Mitochondrial Biogenesis and Oxidative Capacity

Resistance Training in Clinical Populations: T2DM and Metabolic Syndrome

Type 2 Diabetes Mellitus

The evidence base for RT as a therapeutic modality in T2DM is now sufficiently robust to have secured a prominent place in clinical guidelines. The American Diabetes Association (ADA) position statement recommends that individuals with T2DM engage in resistance training at least 2–3 times per week, targeting all major muscle groups, as a component of a comprehensive exercise programme. The rationale is mechanistic (the AMPK and GLUT4 pathways described above are fully operative in T2DM muscle), clinical (meta-analyses consistently demonstrate HbA1c reductions of 0.3–0.6% with RT alone, comparable to some oral hypoglycaemic agents), and functional (RT improves the physical capacity and quality of life of individuals with T2DM, many of whom have concurrent sarcopenia and musculoskeletal limitations) [13,14,15,26].

A 2023 Bayesian meta-analysis examining concurrent aerobic and resistance training in T2DM patients found that combined exercise produced the greatest improvements across multiple cardiometabolic outcomes including HbA1c, fasting glucose, blood pressure, lipids, and body composition, with RT contributing uniquely to lean mass preservation and strength improvements that aerobic training alone did not provide. A dose-response meta-analysis in Frontiers in Endocrinology (2023) further characterised the optimal RT dose for T2DM, finding that ≥3 sessions per week at moderate-to-high intensity (≥70% of 1 repetition maximum [1RM]) achieved the greatest HbA1c reductions [13].

Metabolic Syndrome

Metabolic syndrome , defined by the presence of three or more of the following: waist circumference >102 cm (men)/>88 cm (women), triglycerides ≥150 mg/dL, HDL-C <40 mg/dL (men)/<50 mg/dL (women), blood pressure ≥130/85 mmHg, and fasting glucose ≥100 mg/dL, represents the pre-clinical phase of T2DM and is itself a major independent risk factor for cardiovascular disease. RT has been shown to improve multiple components of metabolic syndrome simultaneously, making it uniquely suited to the management of this multifactorial condition [27].

A systematic review of resistance training in metabolic syndrome found significant improvements in waist circumference, blood pressure, fasting glucose, triglycerides, and HDL-C, effectively addressing all five diagnostic criteria with the magnitude of improvement correlating with baseline severity of dysfunction. This is mechanistically coherent: the greater the degree of insulin resistance, visceral adiposity, and mitochondrial dysfunction at baseline, the more dramatic the metabolic benefit of initiating RT, because each of the pathways activated by exercise is profoundly upregulated relative to a highly dysregulated baseline [5,6,27].

Sarcopenic Obesity: The Emerging Priority

Sarcopenic obesity, the concurrent presence of low skeletal muscle mass/strength and excess adiposity represents a particularly challenging clinical phenotype with a disproportionate metabolic risk burden. Individuals with sarcopenic obesity have insulin resistance attributable to both reduced glucose disposal capacity (from low muscle mass) and increased inflammatory adipokine signaling (from excess adiposity). Conventional weight-loss interventions that focus on caloric restriction without concurrent RT risk worsening this condition by accelerating lean mass loss alongside fat mass reduction, further reducing the muscle metabolic capacity that is essential for long-term weight maintenance [5,14,17,18,24].

RT is the primary evidence-based intervention for improving the lean-to-fat mass ratio in sarcopenic obesity. A 2025 Frontiers in Endocrinology study demonstrated that RT combined with dietary modification achieved superior improvements in body composition, metabolic biomarkers, and physical function compared to dietary modification alone or aerobic exercise combined with diet. Crucially, the lean mass gains achieved through RT persisted over follow-up periods in a way that fat mass reductions from caloric restriction alone did not, suggesting that RT-induced muscle [18,24].

Practical Considerations: Prescribing Resistance Training for Metabolic Health

Dose-Response Relationships

Resistance training, like any therapeutic intervention, operates according to dose-response principles. The key prescriptive variables like frequency, intensity, volume (sets × repetitions × load), rest intervals, and exercise selection, each independently modulate the magnitude of metabolic adaptation. For metabolic health optimization in the general population, the American College of Sports Medicine (ACSM) recommends resistance training 2–3 times per week for all major muscle groups, with 2–4 sets of 8–12 repetitions at 67–85% of 1RM, and rest intervals of 1–2 minutes between sets [25].

In metabolic disease populations, evidence increasingly supports higher intensities and greater volumes than the minimum recommendations. The dose-response meta-analysis in Frontiers in Endocrinology (2023) found that ≥3 sessions per week and intensities of ≥70% 1RM were associated with the largest HbA1c improvements in T2DM. In terms of volume, a minimum of 10 sets per muscle group per week appears necessary to drive meaningful hypertrophy in trained individuals, while beginners may respond to lower volumes initially. Progressive overload, the systematic increase in training stimulus over time is the central principle that distinguishes therapeutic resistance training from recreational weight lifting [13,25].

Exercise Selection and Sequencing

Multi-joint compound exercises (squats, deadlifts, bench press, rows, overhead press) are preferred over isolation exercises for metabolic health applications, as they recruit greater total muscle mass, generate larger hormonal responses (including greater acute growth hormone and testosterone secretion), and impose more substantial metabolic demand (higher caloric cost and EPOC).However, isolation exercises serve an important role in addressing specific muscle group weaknesses, preventing injury, and maintaining training variety [25,30].

For individuals with metabolic disease who are initiating RT, machine-based exercises may be preferable initially for their predictable range of motion and reduced injury risk, transitioning to free weights and compound movements as technique proficiency develops. Bodyweight exercises, particularly loaded progressions (e.g., ring push-ups, Bulgarian split squats, single-leg deadlifts) can achieve comparable metabolic benefits to free weights when appropriately progressed and offer practical advantages for home-based training [26].

Special Populations and Modifications

Individuals with T2DM should monitor blood glucose before, during, and after RT sessions, particularly if on insulin or insulin secretagogues (sulfonylureas), as RT-induced glucose uptake can cause hypoglycaemia. Resistance training produces more predictable glucose responses than aerobic exercise, with smaller acute hypoglycaemia risk, an important practical advantage. Individuals with diabetic peripheral neuropathy require careful attention to footwear and technique to minimise injury risk. Those with diabetic retinopathy should avoid exercises that produce marked intra-abdominal or intraocular pressure elevations (such as very heavy Valsalva-associated lifting) [26].

Older adults with sarcopenia may benefit from higher protein intakes (1.6–2.2 g/kg/day) concurrent with RT to maximise muscle protein synthesis, particularly leucine-enriched protein sources (whey, eggs, soy) that maximally stimulate mTOR-dependent synthetic pathways. Creatine monohydrate supplementation (3–5 g/day), which increases phosphocreatine stores and buffers metabolic perturbation during RT sets, has shown consistent evidence for enhancing lean mass gains and functional performance in older adults, making it a potentially valuable adjunct to RT in this population [28,29].

Integration with Other Modalities

The preponderance of evidence supports the superiority of combined aerobic and resistance training over either modality alone for metabolic health outcomes. The two modalities are mechanistically complementary: aerobic training more powerfully activates AMPK (given its sustained, lower-intensity metabolic perturbation) and produces greater improvements in VO2max and cardiovascular function; RT uniquely drives muscle hypertrophy, strength, and the lean mass-mediated expansion of long-term glucose disposal capacity. The combined modality achieves metabolic benefits that neither can fully replicate alone [3,4,8,16].

For individuals whose primary goal is metabolic health optimization (as distinct from athletic performance), current evidence supports a program structure of 2–3 sessions of RT per week combined with 150–300 minutes of moderate-intensity aerobic activity per week (or 75–150 minutes of vigorous-intensity activity), as recommended by major health organizations. On days combining both modalities, performing RT before aerobic exercise may be preferable for maximizing muscle adaptations, as aerobic exercise performed first can partially blunt the mTOR-dependent anabolic signaling that underpins RT-induced muscle hypertrophy [7,25,26].

Future Directions and Research Frontiers

Several exciting frontiers remain to be fully explored in the intersection of resistance training and metabolic health. First, the field of exercise genomics and personalized training response holds considerable promise. Substantial inter-individual variability exists in the metabolic response to RT, a phenomenon often dismissed clinically but of profound scientific and practical importance. Specific polymorphisms in genes encoding the ACTN3 R577X variant, PPARGC1A (PGC-1α),AMPK subunit genes, and ACE I/D have been associated with differential responses to RT training, and continued work in this area may enable truly personalized exercise prescriptions optimized for individual genotypic profiles [6,11].

Second, the rapidly expanding field of exercise-derived exosome biology represents a frontier of considerable interest. Skeletal muscle releases not only soluble myokines but also extracellular vesicles (exosomes) containing microRNAs, proteins, and lipids that may mediate systemic metabolic communication in ways that soluble proteins cannot fully explain. Exercise-derived exosomes from skeletal muscle have been shown to carry cargo that suppresses hepatic gluconeogenesis and promotes adipose tissue browning, effects that persist long after soluble myokine concentrations have returned to baseline, potentially explaining the prolonged metabolic benefits of exercise observed clinically [2].

Third, the intersection of RT with novel pharmacological approaches, particularly the GLP-1 receptor agonist class (semaglutide, tirzepatide) warrants dedicated investigation. GLP-1 receptor agonists produce profound weight loss but include substantial lean mass loss alongside fat loss, potentially worsening sarcopenia risk in already-vulnerable populations. RT is the most effective strategy for preserving lean mass during pharmacologically induced weight loss, and the combination of GLP-1 receptor agonists with structured RT programs represents a clinically compelling but understudied area with significant implications for long-term metabolic outcomes [18].

Conclusion

The evidence reviewed in this article builds a compelling and multi-layered case for resistance training as one of the most potent metabolic interventions available to modern medicine. From the molecular precision of AMPK-activated GLUT4 translocation to the systemic endocrine orchestration of the myokine secretome; from the structural remodeling of body composition that enlarges long-term glucose disposal capacity to the lipid-lowering and cardiovascular risk-reducing effects mediated through LPL activation and inflammatory suppression; from the restoration of mitochondrial biogenesis and oxidative flexibility to the clinically demonstrated reductions in HbA1c equivalent to those of some oral hypoglycaemics, the metabolic case for resistance training is not merely supported by evidence. It is, in the strongest scientific sense of the word, evidence-based [1,2,5,6,13,15,19,21].

What distinguishes RT from most pharmaceutical interventions is the breadth and simultaneity of its metabolic effects. No single medication improves insulin sensitivity, increases lean mass, reduces visceral fat, lowers triglycerides, raises HDL-C, reduces systemic inflammation, stimulates mitochondrial biogenesis, improves bone density, and confers longevity-associated benefits on cognitive function and all-cause mortality, all through the coherent, evolutionarily conserved molecular programs initiated by working muscle. Resistance training does [27].

In the context of longevity medicine, the argument becomes even more powerful. Skeletal muscle mass is a stronger predictor of all-cause mortality in epidemiological studies than most biomarkers currently measured in standard clinical practice. The progressive sarcopenia of sedentary ageing is not inevitable; it is modifiable through RT even into the ninth decade of life. Investing in skeletal muscle during midlife is, in metabolic terms, the most effective longevity strategy that no prescription can replicate [23,24,27].

The imperative is clear: resistance training should be reconceptualized, by clinicians and patients alike, not as an optional lifestyle enhancement for those who enjoy the gym, but as foundational metabolic medicine, as essential, evidence-based, and urgently prescribed as any pill in the treatment of metabolic disease [26,27].

Reference

1. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–465.

2. Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev. 2020;41(4):594–609.

3. Gao Q, Hu K, Yan C, et al. Effects of aerobic, resistance, interval, and combined training on glucose metabolism in older adults: insights into type, dose, and mechanism. Front Physiol. 2025;16:1702669.

4. Chen Y, Li Y, Li J, et al. The effects of combined exercise training on glucose metabolism and inflammatory markers in sedentary adults: a systematic review and meta-analysis. Sci Rep. 2024;14(1):1958.

5. Sylow L, Kleinert M, Richter EA, Jensen TE. Exercise-stimulated glucose uptake — regulation and implications for glycaemic control. Nat Rev Endocrinol. 2017;13(3):133–148.

6. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–262.

7. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.

8. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013;17(2):162–184.

9. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468.

10. Liu Y, Ye X, Liu Z, et al. Myokines: metabolic regulation in obesity and type 2 diabetes. Life Metab. 2024;3(3):loae006.

11. Schnyder S, Handschin C. Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. Bone. 2015;80:115–125.

12. Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. Adv Physiol Educ. 2014;38(4):308–314.

13. Zhao M, Veeranki SP, Magnussen CG, Xi B. Dose-response relationships of resistance training in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1224161.

14. Lu Y, Kuo HH, Ye X, et al. The efficacy of resistance exercise training on metabolic health, body composition, and muscle strength in older adults with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2025;210:111639.

15. Li D, Shen Y, Chen H, et al. Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effect of changes in muscular strength: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2022;10(2):e002595.

16. Qin L, Chen Y, Zhang C, et al. Effects of exercise training and physical activity advice on HbA1c in people with type 2 diabetes: a network meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025. doi:10.1111/dom.16275.

17. Chen H, Li X, Zhang J, et al. Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: a systematic review and network meta-analysis of 84 randomized controlled trials. Obes Rev. 2024;25(3):e13666.

18. Bott KN, LaBarre JL, Costa S, et al. Resistance training as a key strategy for high-quality weight loss in men and women. Front Endocrinol (Lausanne). 2025;16:1725500.

19. Liu Y, Liu S, Zhong L, et al. The effect of exercise training on blood lipids: a systematic review and meta-analysis. Sports Med. 2025;55(1):163–178.

20. Kelley GA, Kelley KS, Panza GA. Comparison of the effect of endurance, strength and endurance-strength training on glucose and insulin homeostasis and the lipid profile of overweight and obese subjects: a systematic review and meta-analysis. Nutrients. 2022;14(21):4532.

21. Hood DA, Tryon LD, Carter HN, et al. Unravelling the mechanisms regulating muscle mitochondrial biogenesis. Biochem J. 2016;473(15):2295–2314.

22. Camera DM. Anabolic heterogeneity following resistance training: a role for circulating myokines? Front Physiol. 2019;10:1–13.

23. Ramirez-Campillo R, Castillo A, de la Fuente CI, et al. High-speed resistance training is more effective than low-speed resistance training to increase functional capacity and muscle performance in older women. Exp Gerontol. 2014;58:51–57.

24. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943–1955.

25. American College of Sports Medicine. Progression models in resistance training for healthy adults: American College of Sports Medicine position stand. Med Sci Sports Exerc. 2009;41(3):687–708.

26. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–2079.

27. Pedersen BK, Saltin B. Exercise as medicine — evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25(Suppl 3):1–72.

28. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376–384.

29. Candow DG, Chilibeck PD, Forbes SC. Creatine supplementation and aging musculoskeletal health. Endocrine. 2014;45(3):354–361.

30. De Strijcker D, Lapauw B, Ouwens DM, et al. High intensity interval training is associated with greater impact on physical fitness, insulin sensitivity and muscle mitochondrial content in males with overweight/obesity, as opposed to moderate continuous training: a randomized controlled trial. J Musculoskelet Neuronal Interact. 2018;18(2):215–226.